Cocrystal Pharma Completes Dosing in Norovirus Phase 1b Study
TipRanks (Wed, 9-Sep 8:41 AM ET)
Globe Newswire (Wed, 9-Sep 7:00 AM ET)
Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors
Globe Newswire (Mon, 17-Aug 11:17 AM ET)
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health
Globe Newswire (Mon, 3-Aug 7:00 AM ET)
FDA Fast Track for Cocrystal’s CDI-988 Highlights Urgent Need for Norovirus Solutions
Market Chameleon (Thu, 2-Apr 5:52 AM ET)
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
Cocrystal Pharma trades on the NASDAQ stock market under the symbol COCP.
As of September 11, 2026, COCP stock price climbed to $1.24 with 57,140 million shares trading.
COCP has a beta of 2.54, meaning it tends to be more sensitive to market movements. COCP has a correlation of 0.18 to the broad based SPY ETF.
COCP has a market cap of $23.89 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, COCP traded as high as $3.26 and as low as $.76.
The top ETF exchange traded funds that COCP belongs to (by Net Assets): VTI, VXF.
COCP has underperformed the market in the last year with a return of -15.1%, while SPY returned +18.3%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in COCP shares. However, COCP has outperformed the market in the last 3 month and 2 week periods, returning +24.0% and +8.8%, while SPY returned +5.6% and -0.9%, respectively. This indicates COCP has been having a stronger performance recently.
COCP support price is $1.18 and resistance is $1.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COCP shares will trade within this expected range on the day.
